PDF(Pubmed)
Abstract：
BACKGROUND: Early initiation of chemotherapy after surgery for colon cancer has survival benefits. Immediate adjuvant chemotherapy (IAC) involves giving chemotherapy during surgical resection and immediately postoperatively. This novel approach has been shown to be safe, eliminating delays in adjuvant treatment that could increase the risk of micro-metastatic spread. The aim of this study was to assess the willingness of the general public to accept IAC.
METHODS: Between March and April 2021, 800 telephone interviews were conducted with a sample of adult New York State residents. The Survey Research Institute of Cornell University conducted all surveys. Kruskal-Wallis, chi-squared, and Fisher\'s tests were conducted using R 4.0.2.
RESULTS: Three scenarios were presented: (1) receiving IAC resulting in improved survival and quality of life, (2) finishing chemotherapy earlier without survival impact, and (3) finishing chemotherapy earlier but with possible side effects. Respondents with higher education were more likely to accept (1) & (2), males were more likely to accept (2) & (3), higher income respondents were more likely to accept (1) & (3), and those with more work hours were more likely to accept (2). Lastly, 16% responded they would be very or extremely likely, and 52% respondents would be somewhat likely or likely to accept intraoperative chemotherapy, even if it may not be necessary.
CONCLUSIONS: Respondents were likely to accept IAC if offered. Given the known risk of delayed adjuvant chemotherapy (AC) in colon cancer, further research is warranted to determine the survival and quality of life (QOL) benefits of IAC.
METHODS: Between March and April 2021, 800 telephone interviews were conducted with a sample of adult New York State residents. The Survey Research Institute of Cornell University conducted all surveys. Kruskal-Wallis, chi-squared, and Fisher\'s tests were conducted using R 4.0.2.
RESULTS: Three scenarios were presented: (1) receiving IAC resulting in improved survival and quality of life, (2) finishing chemotherapy earlier without survival impact, and (3) finishing chemotherapy earlier but with possible side effects. Respondents with higher education were more likely to accept (1) & (2), males were more likely to accept (2) & (3), higher income respondents were more likely to accept (1) & (3), and those with more work hours were more likely to accept (2). Lastly, 16% responded they would be very or extremely likely, and 52% respondents would be somewhat likely or likely to accept intraoperative chemotherapy, even if it may not be necessary.
CONCLUSIONS: Respondents were likely to accept IAC if offered. Given the known risk of delayed adjuvant chemotherapy (AC) in colon cancer, further research is warranted to determine the survival and quality of life (QOL) benefits of IAC.
摘要：
背景：结肠癌术后早期开始化疗有生存益处。立即辅助化疗（IAC）包括在手术切除期间和术后立即给予化疗。这种新颖的方法已被证明是安全的，消除可能增加微转移扩散风险的辅助治疗延迟。这项研究的目的是评估公众接受IAC的意愿。
方法：在2021年3月至4月之间，对纽约州成年居民进行了800次电话采访。康奈尔大学调查研究所进行了所有调查。Kruskal-Wallis,卡方，和Fisher检验使用R4.0.2进行。
结果：提出了三种情况：（1）接受IAC可改善生存率和生活质量，(2)提前完成化疗而不影响生存,（3）提前完成化疗，但可能有副作用。受过高等教育的受访者更有可能接受(1)&(2)，男性更有可能接受(2)和(3)，收入较高的受访者更有可能接受(1)和(3)，那些工作时间更多的人更有可能接受(2)。最后,16%的人回答说，他们非常或极有可能，52%的受访者可能或可能接受术中化疗，即使可能没有必要。
结论：如果提供，受访者可能会接受IAC。鉴于结肠癌延迟辅助化疗（AC）的已知风险，需要进一步研究以确定IAC的生存和生活质量(QOL)获益.
方法：在2021年3月至4月之间，对纽约州成年居民进行了800次电话采访。康奈尔大学调查研究所进行了所有调查。Kruskal-Wallis,卡方，和Fisher检验使用R4.0.2进行。
结果：提出了三种情况：（1）接受IAC可改善生存率和生活质量，(2)提前完成化疗而不影响生存,（3）提前完成化疗，但可能有副作用。受过高等教育的受访者更有可能接受(1)&(2)，男性更有可能接受(2)和(3)，收入较高的受访者更有可能接受(1)和(3)，那些工作时间更多的人更有可能接受(2)。最后,16%的人回答说，他们非常或极有可能，52%的受访者可能或可能接受术中化疗，即使可能没有必要。
结论：如果提供，受访者可能会接受IAC。鉴于结肠癌延迟辅助化疗（AC）的已知风险，需要进一步研究以确定IAC的生存和生活质量(QOL)获益.
